Helical IMRT Experience in Adult Medulloblastoma Radiotherapy


Aksakal A. K., Tuncer B., Altinişik İnan G., ARAL İ. P., Gani Z., Tezcan Y.

Turk Onkoloji Dergisi, vol.39, no.3, pp.279-285, 2024 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 3
  • Publication Date: 2024
  • Doi Number: 10.5505/tjo.2024.4264
  • Journal Name: Turk Onkoloji Dergisi
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.279-285
  • Keywords: Adult, helical IMRT, medulloblastoma, radiotherapy
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

OBJECTIVE This study aimed to report the characteristics and treatment results of radiotherapy applied with the helical IMRT technique in the adult medulloblastoma patient group. METHODS In this study, adult medulloblastoma patients who received radiotherapy with the Helical Tomo-therapy technique in the Ankara City Hospital Radiation Oncology Clinic between March 2019 and October 2022 were analyzed retrospectively. Primary endpoints are reporting of patients’ survival and toxicity results. RESULTS The analysis was performed on 15 patients. The median follow-up time of the study was 9.4 (1.2–34.7). The median OS is 11.8 (3.9–37.26). The median PFS was 8.5 (1.28–34.73) months. A correlation close to the limit of significance was found between the risk group and PFS (p=0.051). Changes were recorded in the blood values of the patients before the treatment and before the boost treatment. It was determined that the white blood cell (p=0.001) and lymphocyte counts (p=0,001) decreased significantly before the boost treatment. The relationship of these values with lymphocyte count before boost treatment could not be shown statistically. CONCLUSION Radiotherapy with HT technique of adult MBL cases, which we rarely encounter in the clinic, has revers-ible and acceptable acute toxicity rates.